Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention

被引:0
|
作者
David Moriña
Silvia de Sanjosé
Mireia Diaz
机构
[1] Unit of Infections and Cancer - Information and Interventions (UNIC - I&I),
[2] Cancer Epidemiology Research Program (CERP),undefined
[3] Catalan Institute of Oncology (ICO)-IDIBELL,undefined
[4] L’Hospitalet de Llobregat,undefined
[5] Cancer Epidemiology Research Program (CERP),undefined
[6] Catalan Institute of Oncology (ICO)-IDIBELL,undefined
[7] L’Hospitalet de Llobregat,undefined
[8] Centro de Investigación Biomédica en Red (CIBERESP),undefined
[9] Centro de Investigación Biomédica en Red (CIBERONC),undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Markov chain models are commonly used to simulate the natural history of human papillomavirus infection and subsequent cervical lesions with the aim of predicting future benefits of health interventions. Developing and calibrating these models entails making a number of critical decisions that will influence the ability of the model to reflect real conditions and predict future situations. Accuracy of selected inputs and calibration procedures are two of the crucial aspects for model performance and understanding their influence is essential, especially when involves policy decisions. The aim of this work is to assess the health and economic impact on cervical cancer prevention strategies currently under discussion according to the most common methods of model calibration combined with different accuracy degree of initial inputs. Model results show large differences on the goodness of fit and cost-effectiveness outcomes depending on the calibration approach used, and these variations may affect health policy decisions. Our findings strengthen the importance of obtaining good calibrated probability matrices to get reliable health and cost outcomes, and are directly generalizable to any cost-effectiveness analysis based on Markov chain models.
引用
收藏
相关论文
共 50 条
  • [31] Cervical cancer screening in the Philippine setting: A cost-effectiveness analysis
    Ngelangel, CA
    Limson, GM
    Fajutrao, LB
    Cordero, CP
    Javelosa, MA
    Festin, MR
    Ramiro, LS
    Llave, CL
    Abelardo, AD
    VALUE IN HEALTH, 2003, 6 (03) : 230 - 230
  • [32] The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention
    Raab, SS
    Zaleski, MS
    Silverman, JF
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 111 (02) : 259 - 266
  • [33] Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia
    Berkhof, Johannes
    Bogaards, Johannes A.
    Demirel, Erhan
    Diaz, Mireia
    Sharma, Monisha
    Kim, Jane J.
    VACCINE, 2013, 31 : H71 - H79
  • [34] Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses
    Diaz, Mireia
    de Sanjose, Silvia
    Xavier Bosch, F.
    Bruni, Laia
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2018, 23 (06) : 484 - 494
  • [35] COST-EFFECTIVENESS ANALYSIS IN FIRE PREVENTION
    Tuomas, Laine
    INJURY PREVENTION, 2016, 22 : A301 - A301
  • [36] Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis
    Zou, Zhuoru
    Fairley, Christopher K.
    Ong, Jason J.
    Hocking, Jane
    Canfell, Karen
    Ma, Xiaomeng
    Chow, Eric P. F.
    Xu, Xianglong
    Zhang, Lei
    Zhuang, Guihua
    LANCET GLOBAL HEALTH, 2020, 8 (10): : E1335 - E1344
  • [37] Cost-effectiveness analysis: An essential tool to inform public health policy in cervical cancer prevention - Foreword
    Franco, Eduardo L.
    Drummond, Michael F.
    VACCINE, 2008, 26 : F1 - F2
  • [38] THE COST-EFFECTIVENESS OF CERVICAL-CANCER SCREENING
    MILLER, AB
    ANNALS OF INTERNAL MEDICINE, 1992, 117 (06) : 529 - 530
  • [39] Cost-Effectiveness Analysis of Prophylactic Cervical Cancer Vaccination in Japanese Women
    Konno, Ryo
    Sasagawa, Toshiyuki
    Fukuda, Takashi
    Van Kriekinge, Georges
    Demarteau, Nadia
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (03) : 385 - 392
  • [40] Pembrolizumab for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis
    Barrington, David
    Riedinger, Courtney
    Haight, Paulina
    Tubbs, Crystal
    Cohn, David
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S19 - S19